Sorrento Therapeutics, Inc. · OTC:SRNE
Sorrento Therapeutics — IPO Roadshow (June 2019)
36 slides from Sorrento Therapeutics's IPO roadshow presentation, Jun 28, 2019

Slide 1: A Leading Immunotherapy and Non-Opioid Pain Management Company
© 2019 Sorrento Therapeutics, Inc. All Rights Reserved A Leading Immunotherapy and Non - Opioid Pain Management Company June 2019 SRNE (NASDAQ) Filed pursuant to Rule 433 of the Securities Act of 1933 Issuer Free Writing Prospectus dated June 28, 2019 Registration File No. 333 - 221443 Relating to t

Slide 2: Disclaimer
© 2019 Sorrento Therapeutics, Inc. All Rights Reserved 2 Disclaimer Certain statements contained in this presentation or in other documents of Sorrento Therapeutics, Inc . (the “Company” or “Sorrento”) and of any of its affiliates, along with certain statements that may be made by management of the

Slide 3: Investment Highlights
© 2019 Sorrento Therapeutics, Inc. All Rights Reserved Investment Highlights 3 Sorrento is a diversified biopharmaceutical company discovering, developing and commercializing differentiated medicines in areas of high unmet need with breakthrough growth potential ▪ Next generation I - O platform has

Slide 4: Sorrento's Novel Business Model
© 2019 Sorrento Therapeutics, Inc. All Rights Reserved 4 Sorrento’s Novel Business Model ▪ Mission to develop therapeutic approaches that extend and enhance cancer patients’ lives ▪ Innovate and develop high - value - potential non - opioid therapeutics and monetize through strategic transactions ▪

Slide 5: Sorrento Therapeutics – Corporate Structure
© 2019 Sorrento Therapeutics, Inc. All Rights Reserved Sorrento Therapeutics – Corporate Structure 5 58% Ownership Approximately 25% Ownership SP - 102 Commercial - Stage Cell Therapy Joint Venture Immuno - Oncology Joint Venture SRNE (NASDAQ) ▪ Next - Gen Immuno - Oncology Platform : CD38 Immunothe

Slide 6: Multiple Potential Drivers of Future Value
© 2019 Sorrento Therapeutics, Inc. All Rights Reserved ▪ Antibody - centric pipeline leverages Sorrento’s proprietary G - MAB™ library ▪ Anti - CD38 targeting I - O programs for multiple myeloma ‒ Autologous CAR - T – Phase 1 data read - out in Q4 2019 / Q1 2020 ‒ Allogeneic DAR - T – IND filing in

Slide 7: Pipeline & Upcoming Milestones – Sorrento Therapeutics
© 2019 Sorrento Therapeutics, Inc. All Rights Reserved Pipeline & Upcoming Milestones – Sorrento Therapeutics 7 Platform Program Pre - IND IND Phase 1 Pivotal NDA Upcoming Milestones Immuno - Oncology CEA CAR - T (Liver metastases in pancreatic cancer) Pivotal trial beginning in 2H 2019 CD38 CAR - T

Slide 8: Pipeline & Upcoming Milestones – Scilex Pharmaceuticals
© 2019 Sorrento Therapeutics, Inc. All Rights Reserved Pipeline & Upcoming Milestones – Scilex Pharmaceuticals 8 Platform Program IND Phase 1 Phase 2 Phase 3 NDA Approved Upcoming Milestones Non - Opioid Pain Management ZTlido® 1.8% Launched October 2018 Sales of $3.3 million in May 2019 ZTlido® 5.4

Slide 9: Multiple Upcoming Milestones
© 2019 Sorrento Therapeutics, Inc. All Rights Reserved Multiple Upcoming Milestones 9 Expected Timing Program Milestone Q4 2019 CEA CAR - T (liver metastases) – Pivotal trial initiation Q1 2020 RTX (osteoarthritis pain) – Initiate two pivotal trials 1H 2020 SP - 102 (lumbar radicular pain) – Pivotal

Slide 10: Scilex Holding Company
© 2019 Sorrento Therapeutics, Inc. All Rights Reserved Scilex Holding Company

Slide 11: Scilex Pharmaceuticals: Delivering Value Today and Potentially in the Future
© 2019 Sorrento Therapeutics, Inc. All Rights Reserved Scilex Pharmaceuticals: Delivering Value Today and Potentially in the Future 11 Key Recent Achievements March 22, 2019 Announced merger with Semnur Pharmaceuticals June 5, 2019 Announced strong ZTlido® sales growth after successful post - merger

Slide 12: Scilex – ZTlido (FDA approved)
© 2019 Sorrento Therapeutics, Inc. All Rights Reserved US FDA APPROVAL – FEBRUARY 2018 COMMERCIAL LAUNCH – OCTOBER 2018 COMMERCIAL SALES OF $3.3 MILLION IN MAY 2019 12 Scilex – ZTlido ® (FDA approved) Lidocaine Patch Market Overview >3 million prescriptions per year More than 120 million prescriptio

Slide 13: ZTlido: Head-to-Head Adhesion Study
© 2019 Sorrento Therapeutics, Inc. All Rights Reserved 13 1 Data from a 12 patient 12 - hour study Adhesion Scores Over Time (Lower Score Demonstrates Better Adhesion) The recommended scoring system for adhesion of transdermal patches are indicated as follows: 0 = ≥ 90% adhered (essentially no lift

Slide 14: SP-102: On-Track to be the First Steroid Formulation with an FDA-Approved Label
© 2019 Sorrento Therapeutics, Inc. All Rights Reserved Well - tolerated. Key viscous excipient, long history of use including safety SP - 102: On - Track to be the First Steroid Formulation with an FDA - Approved Label to Treat Back Pain 14 Potent non - particulate steroid (injectable dexamethasone

Slide 15: Sorrento's Core Therapeutic Programs
© 2019 Sorrento Therapeutics, Inc. All Rights Reserved Sorrento’s Core Therapeutic Programs

Slide 16: Resiniferatoxin (RTX): A Novel Therapeutic Approach to Osteoarthritis
© 2019 Sorrento Therapeutics, Inc. All Rights Reserved 16 Phase 1b double - blinded, placebo controlled study to assess the safety and preliminary efficacy of intra - articular administration of resiniferatoxin or saline control (as placebo group) for the treatment of moderate to severe pain due to

Slide 17: RTX OA Knee Pain Phase 1b Trial Update: Safety Outcomes
© 2019 Sorrento Therapeutics, Inc. All Rights Reserved RTX OA Knee Pain Phase 1b Trial Update Safety Outcomes (45 Patients. 37 RTX treated. 8 Control) Cohorts RTX Dose (ug) Subjects Progress Blinding Safety 1 5 ug 6 Complete Unblinded No DLT’s 2 12.5 ug 6 Complete Unblinded No DLT’s 3 20 ug 6 Comple

Slide 18: RTX OA Knee Pain Phase 1b Trial Update: Efficacy Outcomes
© 2019 Sorrento Therapeutics, Inc. All Rights Reserved Difference of treatment effect - dose groups relative to control (pooled placebo group) Mean WOMAC A1 Pain Score & Standard deviation 18 RTX OA Knee Pain Phase 1b Trial Update Efficacy Outcomes (All Dose Cohorts Relative to Control ) Dose cohort

Slide 19: RTX OA Knee Pain Phase 1b: Pivotal Dose Candidates
© 2019 Sorrento Therapeutics, Inc. All Rights Reserved Difference of treatment effect (pivotal dose candidates) relative to control (pooled placebo) Patients with more than 50% reduction in reported pain scores 19 RTX OA Knee Pain Phase 1b Trial Update Efficacy Outcomes (Pivotal Dose Candidates Rela

Slide 20: RTX OA Knee Pain Phase 1b: Beyond Study End-Point D84
© 2019 Sorrento Therapeutics, Inc. All Rights Reserved RTX OA Knee Pain Phase 1b Trial Update Efficacy Outcomes (Some Patients Beyond Study End - Point D84) Patients with D168 extended follow - up WOMAC A1 Pain Score 20 Five patients were followed to D168 (protocol trial end - point at D84). These p

Slide 21: Anti-CEA CAR-T Clinical Experience
© 2019 Sorrento Therapeutics, Inc. All Rights Reserved Before Infusion Post - Infusion Anti - CEA CAR - T Clinical Experience 21 Pre - enrollment history Liver metastases of colon or pancreatic cancer Failed 3 lines of conventional chemotherapy and ablation Preliminary Results Complete resolution of

Slide 22: CD38 Multi-Modality Franchise
© 2019 Sorrento Therapeutics, Inc. All Rights Reserved CD38 Multi - Modality Franchise 22 Indication Program Pre - IND IND Phase 1 Pivotal NDA Upcoming Milestones Multiple Myeloma CD38 CAR - T Phase 1 data read - out in Q4 2019 / Q1 2020 CD38 ADC Projected IND filing in 2H 2019 CD38 DAR - T (allogen

Slide 23: In-House CAR-T cGMP Manufacturing Capabilities
© 2019 Sorrento Therapeutics, Inc. All Rights Reserved 23 In - House CAR - T cGMP Manufacturing Capabilities Shorter development times 300 patients per year currently; Next - gen off - the - shelf technology can potentially extend to thousands of patients Reduced manufacturing lead times End - to -

Slide 24: Financial Summary
© 2019 Sorrento Therapeutics, Inc. All Rights Reserved 24 Financial Summary Cash Reconciliation of Sorrento Therapeutics Segment ▪ Un - restricted cash balance of $86 million at December 31, 2018 ▪ One - time expense related to Semnur acquisition (closed in March) ▪ Un - restricted cash balance of $

Slide 25: Multiple Upcoming Milestones
© 2019 Sorrento Therapeutics, Inc. All Rights Reserved Multiple Upcoming Milestones 25 Expected Timing Program Milestone Q4 2019 CEA CAR - T (liver metastases) – Pivotal trial initiation Q1 2020 RTX (osteoarthritis pain) – Initiate two pivotal trials 1H 2020 SP - 102 (lumbar radicular pain) – Pivota

Slide 26: Seasoned Executive Team
© 2019 Sorrento Therapeutics, Inc. All Rights Reserved 26 Seasoned Executive Team Henry Ji, Ph.D. Chairman, President and Chief Executive Officer Deborah Telman, J.D. SVP and General Counsel Jiong Shao, M.B.A. EVP and Chief Financial Officer Gunnar F. Kaufmann, Ph.D. SVP of Immunotherapy & Head of R

Slide 27: Appendix
© 2019 Sorrento Therapeutics, Inc. All Rights Reserved Appendix

Slide 28: From CAR to DAR
© 2019 Sorrento Therapeutics, Inc. All Rights Reserved From CAR to DAR TM scFv Fab TM Chimeric Antigen Receptor (CAR) scFv - based Dimeric Antigen Receptor (DAR) Fab - based linker Hinge Disulfide bond 28

Slide 29: CD38 DAR-T Cells More Potent than CD38 CAR-T Cells at Lower Dose
© 2019 Sorrento Therapeutics, Inc. All Rights Reserved At Lower Dose (4x10e6 Cells), CD38 DAR - T Cells are more Potent than CD38 CAR - T Cells 29

Slide 30: Comparison of DAR-T and CAR-T Cell cGMP Manufacturing Processes
© 2019 Sorrento Therapeutics, Inc. All Rights Reserved Illustrative Comparison of DAR - T Cell and CAT - T Cell cGMP Manufacturing Processes Autologous CAR - T Cell Manufacturing Allogeneic DAR - T Cell Manufacturing 30

Slide 31: Evolution of the Platform: From Auto-CAR-T to Allo-DAR-T
© 2019 Sorrento Therapeutics, Inc. All Rights Reserved Evolution of the Platform: From Auto - CAR - T to Allo - DAR - T Targeting CD38 Clinical Proof - of - Concept CD38 CAR - T Potential Product KOKI CD38 DAR - T Advantages of DAR - T over CAR - T Chimeric Antigen Receptor (CAR) Dimeric Antigen Rec

Slide 32: STI-6129 ADC Exerts Strong Anti-tumor Activity in Myeloma Mouse Model
© 2019 Sorrento Therapeutics, Inc. All Rights Reserved STI - 6129 ADC Exerts Strong Anti - tumor Activity in Myeloma Mouse Model 32

Slide 33: Background on CD38 Target and anti-CD38 mAb
© 2019 Sorrento Therapeutics, Inc. All Rights Reserved 33 Background on CD38 Target and anti - CD38 mAb STI - 5171 Anti - CD38 mAb A2 Fully human antibody selected from GMAB library Both CD38A2 and Daratumumab have nanomolar affinities for recombinant CD38 protein Exhibits fast - on/fast - off bindi

Slide 34: CD38-ADCs Exert Cytotoxicity Against Daratumumab-Resistant MM Cells
© 2019 Sorrento Therapeutics, Inc. All Rights Reserved CD38 - ADCs Exert Cytotoxicity Against Tumor Cells f rom Daratumamab - Resistant MM Patients 34 Primary MM cells MACS separated and frozen (5x10 e6 cells) Thawed 6 patients CD138+ fractions 4 patient samples could be evaluated Dara samples cultu

Slide 35: RTX OA Knee Pain Phase 1b: Additional Cohorts Being Considered
© 2019 Sorrento Therapeutics, Inc. All Rights Reserved RTX OA Knee Pain Phase 1b Trial Update Additional Cohorts Being Considered Prior to Pivotal Studies 35 Sedation & Local Analgesia Administration protocols at 12.5 ug dose (in progress) Limited pre - administration opioids with local supportive n

Slide 36: Upcoming RTX Milestones
© 2019 Sorrento Therapeutics, Inc. All Rights Reserved Upcoming RTX Milestones (By Indication and Target Dates) Osteoarthritis Knee Pain Phase 1b to conclude in 2019 Two Phase 3 pivotal trials to start in 1 st half 2020 (USA and Asia - Pacific) Support Phase 2 trials in planning, for implementation
Source: SEC EDGAR · FWP filed Jun 28, 2019
More decks from Sorrento Therapeutics, Inc.
Presentation (August 2023)9 slides · Aug 1, 2023
SPAC Merger (March 2022)21 slides · Mar 18, 2022
Technical Presentation (January 2022)13 slides · Jan 21, 2022
SPAC Merger (December 2021)57 slides · Dec 13, 2021
Technical Presentation (November 2021)9 slides · Nov 29, 2021
Investor Presentation (September 2021)37 slides · Sep 13, 2021